Kimberly K. Scarsi

Kimberly K. Scarsi

Auto-generated profile, based on publicly available information

Kimberly K. Scarsi

Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Drugs
Verified
Journal Article
Closed access
PDF file
KSKimberly K. Scarsi
Kimberly K. Scarsi
JHJoshua P. Havens
Joshua P. Havens
APAnthony T Podany
Anthony T Podany
SASean Avedissian
Sean Avedissian
CFCourtney V Fletcher
Courtney V Fletcher

1 November 2002 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
KSKimberly K. Scarsi
Kimberly K. Scarsi
MFMichael A. Fotis
Michael A. Fotis
GNGary A. Noskin
Gary A. Noskin
Kimberly K. Scarsi, Pharm.D., Michael A. Fotis, B.S.Pharm., Gary A. Noskin, M.D.; Pharmacist participation in medical rounds reduces medication errors, America

14 August 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JHJoshua P Havens
Joshua P Havens
KSKimberly K Scarsi
Kimberly K Scarsi
HSHarlan Sayles
Harlan Sayles
DKDonald G Klepser
Donald G Klepser
SSSusan Swindells
Susan Swindells
SBSara H Bares
Sara H Bares
Background: Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in the PrEP care process may help increase access to PrEP services. Methods: Our pharmacist-led PrEP program (P-PrEP) included pharmacists from a university-based HIV clinic, a community pharmacy, and 2 community-based clinics. Through a collaborative practice agreement, pharmacists conducted PrEP visits with potential candidates for PrEP, according to the recommended Centers for Disease Control and Prevention guidelines, and authorized emtricitabine-tenofovir disoproxil fumarate prescriptions. Demographics and retention in care over 12 months were summarized, and participant satisfaction and pharmacist acceptability with the P-PrEP program were assessed by Likert-scale questionnaires. Results: Sixty patients enrolled in the P-PrEP program between January and June 2017 completing 139 visits. The mean age was 34 years (range, 20–61 years), and 88% identified as men who have sex with men, 91.7% were men, 83.3% were white, 80% were commercially insured, and 89.8% had completed some college education or higher. Participant retention at 3, 6, 9, and 12 months was 73%, 58%, 43%, and 28%, respectively. To date, no participant has seroconverted. One hundred percent of the participants who completed the patient satisfaction questionnaire would recommend the P-PrEP program. Pharmacists reported feeling comfortable performing point-of-care testing and rarely reported feeling uncomfortable during PrEP visits (3 occasions, 2.2%) or experiencing workflow disruption (1 occasion, 0.7%). Conclusions: Implementation of a pharmacist-led PrEP program is feasible and associated with high rates of patient satisfaction and pharmacist acceptability.

1 March 2014 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
PDF file
PGPaul Gubbins
Paul Gubbins
MKMichael E. Klepser
Michael E. Klepser
AAAlly Dering Anderson
Ally Dering Anderson
KBKarri A. Bauer
Karri A. Bauer
KDKristin M. Darin
Kristin M. Darin
KSKimberly Scarsi
Kimberly Scarsi

17 June 2016 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
APAnthony T. Podany
Anthony T. Podany
KSKimberly K. Scarsi
Kimberly K. Scarsi
CFCourtney V Fletcher
Courtney V Fletcher

27 March 2018 in AIDS
Verified
Journal Article
Closed access
APAnthony T Podany
Anthony T Podany
SBSara H. Bares
Sara H. Bares
JHJoshua Havens
Joshua Havens
SDShetty Ravi Dyavar
Shetty Ravi Dyavar
JOJennifer O’neill
Jennifer O’neill
KSKimberly K. Scarsi
Kimberly K. Scarsi
Objectives: The aim of the study was to compare the intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics of tenofovir (TFV) and its intracellular metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet of TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat (COBI) to a FDC containing TFV alafenamide (TAF)/FTC/EVG/COBI. Design: A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic study in patients receiving a TDF-containing regimen (TDF 300 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg) switched to a TAF-containing FDC regimen (TAF 10 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg). Methods: Single, sparse plasma and PBMC samples were collected during TDF therapy and 4–8 weeks post-switch to the TAF-containing regimen. Plasma TFV and cell associated TFV-DP concentrations were determined with validated liquid chromatography tandem mass spectrometry methods. PBMC cell enumeration was performed by quantification of RNaseP (RPP30) gene copy numbers using a highly sensitive droplet digital PCR assay. Plasma and PBMC pharmacokinetics were summarized as geometric mean and compared as a geometric mean ratio with a Wilcoxon signed-rank test. Results: In 30 participants with evaluable data, TFV plasma concentrations decreased 90% [TDF: 99.98 (2.24) ng/ml vs. TAF: 10.2 (1.6) ng/ml, P < 0.001] after the switch while cell-associated TFV-DP increased 2.41-fold [TAF: 834.7 (2.49) vs. TDF: 346.85 (3.75) fmol/106 cells, P = 0.004]. Conclusion: Intraindividually, plasma TFV concentrations significantly decreased while cell associated TFV-DP concentrations significantly increased after switching from a TDF to a TAF-containing antiretroviral therapy regimen.